HMS
LOE ApproachingNDAOPHTHALMICSUSPENSION
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
HMS by AbbVie is clinical pharmacology hms (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Approved for allergic conjunctivitis, vernal conjunctivitis, episcleritis and 1 more indications. First approved in 1969.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HMS (medrysone ophthalmic suspension) is a synthetic corticosteroid approved in 1969 for topical ophthalmic use. It reduces inflammation in allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity by inhibiting edema, fibrin deposition, and phagocytic migration. HMS has lower anti-inflammatory potency than dexamethasone 0.1%, positioning it as a milder alternative.
LOE Approaching
Product is in advanced lifecycle stage with competitive pressure at 30%, signaling possible team consolidation or transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY HMS (medrysone ophthalmic suspension) is a synthetic corticosteroid with topical anti-inflammatory activity. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation and phagocytic migration of the acute inflammatory response as well as capillary proliferation,…
Indications (4)
Worked on HMS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.